Evx-02A
Melanoma Stage III
Evaxion Biotech A/SPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Melanoma Stage III cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bnt111 BioNTech SE | Phase 2 | B |
DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301) Syneos Health | Phase 2 | CCC |
L19IL2/L19TNF Philogen S.p.A. | Phase 2 | CCC |
kb707 Krystal Biotech, Inc. | Phase 1/2 | CC |
Evx-02B Evaxion Biotech A/S | Phase 1/2 | CC |
View all 13 →
Same molecule, other indications
Evx-02A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →